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Summary The orally administered tubulin-binding agent 1069C85 was developed with the hope of overcoming the multidrug resistance
associated with existing anti-tubulin agents, such as the vinca alkaloids. A phase study was performed using a single oral dose every 3
weeks, administered as a suspension reconstituted in 0.1% Tween 80 and 0.9% saline. The starting dose was 2.8 mg m-2, and dose doubling
was permitted until the area under curve (AUC) was .40% of that at the mouse LD10; thereafter, a modified Fibonacci scheme was used. The
formulation proved to be unsatisfactory, resulting in inconsistent absorption. The terminal elimination half-life was prolonged (range 18-73.5 h).
Sporadic central neurotoxicity was observed, which was grade 3 in one patient treated at 200 mg mn2. A revised formulation with micronized
drug was more easily suspended and appeared to increase the bioavailability by a factor of 2-4. Severe central neurotoxicity, up to grade 4,
was then observed at doses of 50-100 mg m-2. Unfortunately, toxicity was not predictable and one patient, with a previous history of partial
intestinal obstruction, treated at 50 mg m-2, cleared the drug very slowly, possibly because of prolonged, delayed absorption. This patient died
from pancytopenia and severe gastrointestinal damage. It was concluded that such unpredictable behaviour would be incompatible with safe
evaluation in phase 11 studies; the trial was closed and further clinical development abandoned.
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The tubulin-binding agent 1069C85 was developed from a struc-
ture activity investigation of tubulin inhibitors binding at the
colchicine site on tubulin. The addition of the trimethoxybenzyl
moiety, which is shared by colchicine and podophyllotoxin, to a
series ofimidazopyridazine carbamates that inhibit polymerization
of tubulin from the nematode led to the identification of 1069C85
(see Figure 1) (Hodgson et al 1992; Hodgson, 1994) This modifi-
cation conferred selectivity for binding to the colchicine site on
mammalian tubulin together with potent inhibition oftubulin poly-
merization at concentrations that were cytotoxic to P388 cells. In
preclinical studies, 1069C85 retained activity against murine
tumour cell lines with acquired resistance to a variety of natural
anti-cancer products (Hodgson et al, 1992; Hodgson, 1994).
Subsequent investigations in human tumour cell lines confirmed
these findings (Raynaud et al, 1994)
Because of extremely poor aqueous solubility, it did not prove
feasible to develop a satisfactory formulation for intravenous use.
However, anti-tumour activity of 1069C85 was confirmed in vivo
via the oral route using a variety of murine tumours. No studies
were performed using human tumour xenografts. Preclinical phar-
macokinetic studies showed that oral bioavailability was relatively
poor, varying from 7% in dog, for which an i.v. formulation using
dimethyl isosorbide was used (data on file, Glaxo/Wellcome 1990),
to 20% in mouse, in which the i.v. vehicle was dimethylsulphoxide
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(DMSO)/saline (Raynaud et al, 1994). The plasma elimination
half-life following oral administration (p.o.) varied markedly
depending on the species, being approximately 16 h in dog (Data
on file 1990), 2 h in monkey (data on file Glaxo/Wellcome, 1990)
and 8 h in mouse (Raynaud et al, 1994). Protein binding in mouse
was high, estimated to be 85-99%. There was a linear relationship
between dose and area under curve (AUC) using the oral route
over the dose range 1-20 mg kg-', i.e. up to 60 mg m-2, r2 = 0.87
(Raynaud et al, 1994). Above this dose, absorption was saturated;
however 20 mg kg-' was known to be an active dose.
Toxicity studies in rodents have shown that myelosuppression
and gastrointestinal damage are dose limiting (data on file, Cancer
Research Campaign, 1993). The LD,O for a single oral dose in
mice was 142.2 mg m-2 and 39.6 mg m-2 ifgiven intraperitoneally
(i.p.). Repeat-dose studies in mouse and rat using a daily x 5 for 4
weeks schedule suggested that toxicity was schedule dependent as
repeat dosing above 3.9 mg m-2 i.p. proved to be fatal in mouse,
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Figure 1 Structure of 1069C85
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and a similar study at 14.3 mg m-2 p.o., i.e. one-tenth ofthe mouse
single dose PO LD,(, proved to be fatal in seven out of ten
animals; surviving animals showed body weight loss. The degree
of gut mucosal damage was similar if the drug was administered
either i.p. or p.o.; hence this was not thought to be as the result of
a local effect.
METHODS
Formulation and drug administration
A formulation was developed at the Cancer Research Campaign
Formulation Unit. The drug was dispensed into vials as a dry
powder and reconstituted as a fine suspension by administration of
0.9% saline containing 0.1% Tween 80 (polysorbate) with
vigorous mixing. Immediately before oral administration, the drug
suspension was mixed with orange juice both to disguise any
possible unpleasant taste and to help ensure complete ingestion.
Stability studies were performed that showed no effect of orange
juice on the stability of 1069C85. Patients were treated following a
10-h fast, given the known limited bioavailability, although no
data were available regarding the effect offood on absorption.
In practice, it proved difficult to produce a uniform, stable
suspension and the persistence ofunsuspended particles in the vial
following reconstitution gave rise to serious concerns that patients
might be underdosed or that the delivered dose might be inconsis-
tent. This led to a revised formulation in which the drug was
micronized before being dispensed into vials. This resulted in the
formation ofan improved suspension with less material remaining
at the bottom of the vial before drug administration. No changes
Table 1
Patient characteristics Number
Age (years)
Median (range) 53 (26-73)
Sex
Female 29
Male 10
Performance status
0 5
1 27
2 7
Tumour type
Ovary 16
Breast 5
Sarcoma 4
Lung 3
Colorectal 3
Melanoma 2
Unknown primary 2
Mesothelioma 2
Stomach 1
Tonsil 1
No. of previous chemotherapy regimens
1-2 23
>3 16
No. of courses of 1069C85
Mean (range) 2.4 (1-12)
Total 97
were made to the reconstitution procedure. Preclinical studies with
1069C85 in mice suggested that bioavailability might be increased
two-threefold (F I Raynaud, personal communication).
Patient eligibility
Patients were required to have a histologically proven diagnosis of
cancer and either to have become refractory to standard therapy or
to have a disease for which no standard therapy was available.
Other eligibility criteria were also standard for a phase I trial, i.e.
age > 18 years, WHO performance status <2, life expectancy > 3
months, no chemotherapy for 4 weeks, WBC .3 x 109 1-1,
neutrophils .2 x 1091-, platelets .100 x 109 1-', bilirubin <25 gmol
1-', alkaline phosphatase <200 IU 1-', alanine aminotransferase <100
IU 1-', creatinine <130 ,tmol 1-', and written informed consent.
Study design
The starting dose was 2.8 mg m-2. Taking note of the fact that rats
did not tolerate repeat dosing at one-tenth of the mouse LD1O and
fatal toxicity was observed in dogs at 20 mg m-2, the decision was
taken to start at only 20% of the usual phase I starting dose, i.e.
one-tenth ofthe mouse LD1O. Although, it was acknowledged that
both toxicity and anti-tumour activity could be schedule depen-
dent, it was decided that for safety reasons the first phase I study
should be performed using a single oral dose every 3 weeks. In
principle, it was the intention to perform a pharmacokinetically
guided dose escalation (PGDE) as there was a linear relationship
between dose and AUC in the mouse (Raynaud et al, 1994), and it
was hoped that the drug would be detectable in the plasma using
HPLC at the starting dose. During the PGDE phase, the dose was
to be doubled until the AUC was 40% of that at the murine LDMI,
subsequent escalations followed a 'modified Fibonacci' scheme.
Three patients were to be treated at each dose level. The maximum
tolerated dose was defined as grade 3 antiproliferative toxicity
(excluding alopecia) in .40% patients or grade 2 organ-specific
toxicity in two or more patients. One intra-patient escalation was
allowed if no patient had experienced > grade one toxicity after 6
weeks of observation (two cycles) at the proposed dose. A
minimum 1-week interval was required between the first and
second patients at each dose level oncetoxicity had been observed.
Response and toxicity assessment
Although response rate was not an end point in this phase I study,
responses were assessed, where possible, using standard criteria.
No formal requirement for assessability was required before study
entry. Patients were seen weekly after treatment, and blood
samples were taken for full blood count and biochemistry. Toxicity
was graded according to CTC criteria, and daily diary cards
were completed by the patients to ensure the accuracy of this
information.
Pharmacokinetics
Blood samples for pharmacokinetics were taken from an in-
dwelling cannula at 0, 5, 10, 20, 30, 45, 60, 90 min, 2, 3, 4, 6, 8, 12
and 24 h following treatment. In patients treated at doses >50 mg
m-2 a 48-h sample was added and, in patients treated with the
micronized formulation, an additional sample was collected on
day 7. Plasma was separated and stored at -20°C until analysis.
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Table 2 1069C85: Toxicity profile (grading according to Common Toxicity Criteria)
CTC toxicity grade
Neurotoxicity Neutropenia Thrombocytopenia Diarrhoea Nausea/ Alopecia
vomiting
Dose(mg m-2) No. of patients 1 2 3 4 1 2 3 4 1 2 3 4 1 2 1 2 1 2
2.8 3 1
5.6 3 1 1
11.2 7 1 1 1
22.4 5 1 1
35.8 4 1
50 2
100 4 2 1 1
200 5 3 1 1 1
Micronized
25 5 1 1
50 3 1 1 1 1 1
100 2 1 1 1 1
Table 3 Relationship between pharmacokinetics and central neurotoxicity in selected patients
Dose Symptoms Neurotoxicity AUC Cmax
(mg m-2) (CTC grade) (ItM h) (.g l-i)
10oa Vivid dreams, disturbed sleep; days 3-6 1 53.9 90
200 Visual disturbance, flashing lights 1 5.1 100
200 Ataxia, confusion, disorientation; days 2-6 3 15.2 159
50a Agitation, confusion and visual hallucinations; days 2-6b 3 16.4 327
100a Ataxia, confusion, hallucinations, coma; days 2-7b 4 23.4 495
aMicronized formulation; patients treated at 100 mg m-2 were previously treated with non-micronized at 200 mg m-2. bThis patient died on day 8 from
myelosuppression and gut toxicity. cDrug detectable in the cerebrospinal fluid 7 days after dosing; patient also suffered myelosuppression and alopecia.
The samples were analysed using high-performance liquid chro-
matography (HPLC) with fluorescence detection according to the
method described by Raynaud (1993). Curves were fitted using
PCNONLIN version 4.0 software to determine elimination half-
life(tl12), and the AUC was calculated using the trapezoidal rule up
to 24 h. No weighting was used. Extrapolation to infinity was not
performed owing to the long terminal t12 and paucity of late time
points. The extent of protein binding in human plasma was deter-
mined by centrifugation across Amicon protein exclusion
membranes at 25°C using the same HPLC method to estimate
1069C85 in the original plasma and the filtrate.
Ethical considerations
The study was approved by the Research Ethics Committee ofthe
Royal Marsden Hospital, UK. All patients were required to give
written consent a minimum of 1 week after initial consultation and
were given full written information concerning 1069C85 and the
study design. The study was conducted according to the
Declaration ofHelsinki under the auspices ofthe Cancer Research
Campaign (CRC) Phase V1l Committee and was monitored by the
CRC Data Centre.
RESULTS
A total of39 patients were treated over the dose range 2.8-200 mg
m-2. Thirty-three patients received the non-micronized formulation
and ten received the micronized formulation. Fourpatients received
both formulations. The demographic details are given in Table 1.
Non-micronized formulation
Dose escalation
There was no detectable taste and complete ingestion was achiev-
able. The dose was escalated by 100% increments from 2.8 to 22.4
mg m-2 over which dose range grade 1-2 nausea and vomiting
were the only toxicities observed. Dose escalation steps were then
reduced, according to the modified Fibonacci scheme. It appeared
that absorption had become saturated at 50 mg m-2 as no signifi-
cant increase in mean AUC had been observed for two dose levels.
Two further 100% dose escalations were performed, at which point
dose limiting toxicity was observed.
Toxicity
The main toxicities observed are summarized in Table 2. Using the
original formulation, no antiproliferative toxicities were observed
and, apart from sporadic grade 1 and 2 nausea and vomiting, they
did not appear to be dose related. This occurred several hours after
drug administration, and it was not thought likely that the patients
vomited unabsorbed drug. The only serious side-effect observed
was central neurotoxicity, mainly mild sedation. This occurred in
four of five patients treated at 200 mg m-2 but was only severe
(grade 3) in one patient, see Table 3. This patient experienced
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Table 4 Pharmacokinetics of 1069C85 (mean values, ± standard deviation if > three patients)
Dose (mg m-2) AUC (gg 1-1 h-1) Cmax (hg 1-') T,.,, (h) t1n (h)
(No. of patients)
Non-micronized
2.8(3) 69.9 (±30.2) 7.3 (±3.4) 10 (±7.1) 29 (+22)
5.6(2) 209.7 13 9.5 39.5
11.2(4) 371.5 (±178.7) 21.7 (±11.3) 5.3 (±1.2) 23.2 (±6.9)
22.4(3) 476.4 (±206.8) 25.9 (±11.4) 7.6 (±1.9) 35.7 (±15.1)
35.8(4) 507.5 (±153.6) 33 (±13.9) 7.8 (±3.4) 22.9 (±19.5)
50(2) 423.3 22 7.2 73.5
100(4) 844.7 (±314.7) 48.5 (±25) 4.8 (±1.1) 23 (±4.3)
200(4) 3011 (±1771.4) 99.8 (±36.9) 8.8 (±1.9) 18.2 (±3)
Micronized
25(5) 1061.8 (±269.1) 58.6 (±19.5) 9.8 (±3.2) 38.9 (±36.9)
35.8(1) 1262.3 70.7 6.3 16.3
50(2) 3786.9 198.9 10.6 24
100(2)a 15011.7 292.3 6.1 24.7
aPatients treated at 100 mg m-2 with the micronized formulation had previously been treated at 200 mg m-2 using the standard formulation.
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Figure 2 Typical plasma profile of 1069C85 showing slow absorption and
subsequent slow elimination in a patient treated at 35.8 mg m-2
ataxia, slurred speech, drowsiness, vivid hallucinations and confu-
sion. The onset ofsymptoms occurred 48 h after dosing and lasted
for 7 days. This patient was taking phenytoin forepilepsy, and the
possibility ofphenytoin toxicity due to displacement from plasma
proteins was considered initially, however her plasma phenytoin
level proved to be within the therapeutic range.
Pharmacokinetics
The pharmacokinetic data are summarized in Table 4. Absorption
of 1069C85 was variable with time to maximum plasma concen-
tration (Tmx) varying from 1.4 to 20 h. C!m, was less variable for a
given dose, but AUC varied markedly. Elimination fitted a one-
compartment model with a long terminal half-life which was
extremely variable (range 7-107 h). Mean values according to
dose are given in Table 4, the overall median value was 24h. The
variability in AUC and terminal half-life is partly because of the
fact that, in the first cohort of 18 patients, plasma samples were
only collected for the first 24 h. A typical plasma profile showing
absorption and slow elimination is shown in Figure 2. Although
absorption was initially thought to have been saturated at 50 mg
m-2, further increases in dose did result in increases in Cmax and
Figure 3 Plasma profiles of patients treated using the micronized formulation
at doses of 25 mg m-2 (-x-x-) and 50 mg m-2( * * ), including
patient 39 who exhibited prolonged maintenance of high plasma
concentrations over the 48-h period of blood sampling
AUC. The Cmax ofthepatient experiencing grade 3 neurotoxicity at
200 mg m-2 was 159 gg ml-'. Protein binding was found to be
extremely high in man at >99%.
Micronized formulation
Dose escalation
The revised formulation was superior in terms ofease ofreconsti-
tution, and ten patients were treated over the dose range 25-100
mg m-2. Only patients previously treated without toxicity at 200
mg m-2 received I mg m-2.
Toxicity
Toxicities are summarized in Table 2. No significant toxicities were
observed at 25 or 35.8 mg m-2. At 50 mg m-2, plasma concentra-
tions in the first patient treated were similar to those observed with
the non-micronized formulation at 200 mg m-2, and the 25 mg m-2
dose level was expanded to fivepatients. One patient treated at 100
mg m-2, having previously had no serious toxicity at 200 mg m-2,
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experienced severe grade 4 neurotoxicity consisting of ataxia,
confusion, hallucinations and coma, see Table 3. Once more, the
onset was at approximately 48 h and lasted for 10days. This patient
also experienced grade 3 neutropenia and grade 2 alopecia. In both
cases of severe neurotoxicity, the hallucinations were described as
exceedingly vivid, 'like watching a film', and were associated with
paranoid thoughts, such as being kidnapped. This was quite fright-
ening for one patient, who subsequently required careful coun-
selling. The dose was reduced again to 50 mg m-2. Unfortunately,
this patient also developed grade 3 neurotoxicity, followed at day
6 by the rapid onset of grade 4 neutropenia, grade 3 thrombocy-
topenia and grade 2 vomiting and diarrhoea. The patient was
treated intensively with intravenous fluids and broad spectrum i.v.
antibiotics but died on day 8. At autopsy, the main findings were
extremely advanced ovarian cancer extending throughout the peri-
toneal cavity and evidence of extensive mucosal damage to small
intestine and colon. Death was attributed to 1069C85. She had
suffered from episodes of partial intestinal obstruction but, imme-
diately before treatment, had been eating normally for more than
two weeks, had a good performance status and the serum albumin
was >30 g 1-'. Following the death ofpatient no. 39, it was decided
to close the study.
Pharmacokinetics
The pharmacokinetics are summarized in Table 4. Micronization
of 1069C85 appeared to increase the oral bioavailability by a
factor of 2-4. It was clear that central neurotoxicity correlated with
C,l,ax in that the three highest values of 159, 327 and 495 ng ml
were seen in patients with grade 3 or 4 toxicity. In the most
severely affected patient, drug was still detectable in the cere-
brospinal fluid at 8 days. Severe neurotoxicity was not observed at
C11ax <100 ng ml'. AUC did not correlate with toxicity, but this
may be misleading as the entire elimination profile was not
defined in the majority ofpatients in spite of sample collection for
48 h. The plasma profile ofthe patient who died ofrapid onset gut
and bone marrow toxicity is shown in Fig 3.
Responses
There were no objective responses to 1069C85.
DISCUSSION
It is acknowledged that resistance to anti-cancer agents is multifac-
torial. However, multidrug resistance associated with P-glycopro-
tein expression is believed to be important. It has been suggested
that the outlook in chemosensitive diseases, such as childhood
sarcomas, is significantly poorer in patients with P-glycoprotein
overexpression (Chan et al, 1990). Although, to date, studies in
adult solid tumours have been disappointing with the agents
currently available, a number of studies in haematological malig-
nancy and childhood cancer have demonstrated the ability of
modulating agents to reverse clinical drug resistance (Durie et al,
1988; Dalton et al, 1989; Miller et al, 1991; Sonneveld et al, 1992;
Cowie et al, 1995). A new agent in the tubulin-binding class that is
not a good substrate for P-glycoprotein would be highly desirable
(Raynaud et al, 1994).
Unfortunately, attempts to increase the aqueous solublity of
1069C85 by chemical modification are said to result in loss of the
ability to overcome multidrug resistance, and conversely the reten-
tion of this property is associated with the ability to cross the
blood-brain barrier. In the light of data derived from work in
P-glycoprotein knockout mice, it is possible that neurotoxicity is
directly related to the fact that this agent is not a substrate for P-
glycoprotein. In a study of vinblastine pharmacokinetics, van
Asperen et al (1996) found substantially greater accumulation of
drug in the brains of P-glycoprotein-deficient mice than in wild-
type mice, in addition to reduced faecal excretion. The need to
give the drug orally created additional problems and illustrates the
difficulty ofdeveloping a new orally administered cytotoxic agent.
The combination ofa phase-specific drug, poor oral bioavailability
and long terminal half-life led to a situation in which fatal antipro-
liferative toxicity occurred at a previously safe dose.
Preclinical studies predicted that gut and bone marrow toxicities
would be dose limiting and that schedule dependency was to be
expected (Data on file, GlaxolWellcome, 1990, Cancer Research
Campaign, 1993). The long terminal half-life of approximately 24
h observed from the start of the study suggested that a repeat
schedule might not be required to achieve an anti-tumour effect.
However, it must be remembered that 1069C85 is highly protein
bound, hence the long half-life does not necessarily reflect persis-
tence of free drug. Difficulties with the formulation and the wide
interpatient variability in absorption were cause for serious
concern. The central nervous system neurotoxicity appeared to be
dose limiting and was clearly associated with high peak plasma
concentrations, only being severe above 100 tg 1-'. It had seemed
possible that some form of intermittent schedule at doses low
enough to avoid such peak concentrations might overcome the
acute toxicity. However, as shown in Figure 3, although patient no.
39 did not have the highest C,i,ax and AUC observed, toxic plasma
concentrations were maintained for longer than in other patients
resulting in fatal antiproliferative toxicity. In the case ofthe tubulin
inhibitor paclitaxel, it has been shown that myelosuppression is
associated with maintenance of plasma concentrations above a
certain threshold (Gianni et al, 1995). The likely explanation for
the anomalous plasma profile in this patient appears to be that
because of partial intestinal obstruction the drug continued to be
absorbed from the small intestine for much longer that in patients
with a normal transit time. Even in those without intra-abdominal
malignancy, cancer patients often have poor bowel function
because of the use of opiates. The unpredictability of such severe
toxicity is clearly unacceptable and no further development of
1069C85 is planned.
It is of interest that a similar compound (in terms of its preclin-
ical profile, albeit a different structure), CI-980, has produced a
similar pattern of toxicities. CI-980 differs in that it is sufficiently
soluble to be administered parenterally, allowing different sched-
ules of administration to be investigated. It was also developed
with the rationale that a tubulin inhibitor which overcame
multidrug resistance would be of interest. In phase I trials, a 24 h-
infusion schedule produced dose limiting central neurotoxicity,
including ataxia, confusion and coma, of very similar type to
1069C85 (Sklarin et al, 1995), while a more prolonged 72 h-infu-
sion caused dose limiting myelosuppression (Rowinsky et al,
1995). The same conclusions were drawn, i.e. that neurotoxicity
was associated with a high peak plasma concentration while
antiproliferative toxicities were associated with maintenance of
toxic concentrations above a threshold. It is possible that repeat or
prolonged administration would also be more effective against
tumours, although this remains to be proven with another tubulin-
active agent, paclitaxel (Eisenhauer et al, 1994).
In conclusion, it was unfortunate that, although the ability to
overcome multidrug resistance was confirmed in a number of
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human tumour models, the pharmaceutical properties of 1069C85
did not allow this to be exploited safely in patients. Nevertheless,
the ability to treat tumours exhibiting resistance due to overexpres-
sion ofP-glycoprotein is a worthwhile goal. The fact that, in prin-
ciple, this can be achieved by appropriate drug design without the
use of modulating agents, is encouraging.
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